Abstract
Earlier autoradiographic studies with the 5-HT2 receptor agonist [125I](±)DOI in human brain showed unexpected biphasic competition curves for various 5-HT2A antagonists. We have performed similar studies in rat brain regions with selective 5-HT2A (M100907) and 5-HT2C (SB242084) antagonists together with ketanserin and mesulergine. The effect of GTP analogues on antagonist competition was also studied. Increasing concentrations of Gpp(NH)p or GTPγS resulted in a maximal inhibition of [125I](±)DOI-specific binding of approximately 50 %. M100907 competed biphasically in all regions. In the presence of 100 μM Gpp(NH)p, M100907 still displaced biphasically the remaining [125I](±)DOI binding. Ketanserin showed biphasic curves in some regions and monophasic curves in others. In the latter, Gpp(NH)p evidenced an additional high-affinity site. SB242084 competed biphasically in brainstem nuclei and monophasically in the other regions. In most areas, SB242084 affinities were not notably altered by Gpp(NH)p. Mesulergine competed monophasically in all regions without alteration by Gpp(NH)p. These results conform with the extended ternary complex model of receptor action: receptor exists as an equilibrium of multiple conformations, i.e. ground (R), partly activated (R*) and activated G-protein-coupled (R*G) conformation/s. Thus, [125I](±)DOI would label multiple conformations of both 5-HT2A and 5-HT2C receptors in rat brain, and M100907 and ketanserin would recognise these conformations with different affinities.
Similar content being viewed by others
Abbreviations
- Acb:
-
Accumbens
- ChP:
-
Choroid plexus
- Cl:
-
Claustrum
- CPu:
-
Caudate-putamen
- FCx:
-
Frontal cortex
- Tu:
-
Olfactory tubercle
- 7:
-
Facial nucleus
- 10:
-
Dorsal motor nucleus of vagus
- 12:
-
Hypoglossal nucleus
References
Adlersberg M, Arango V, Hsiung S, Mann JJ, Underwood MD, Liu K, Kassir SA, Ruggiero DA, Tamir H (2000) In vitro autoradiography of serotonin 5-HT(2A/2C) receptor-activated G protein: guanosine-5′-(gamma-[(35)S]thio)triphosphate binding in rat brain. J Neurosci Res 61(6):674–685
Aloyo VJ, Salt GL, Hoffman ME, Harvey JA (1998) Agonist and antagonist binding to rabbit cortical 5-HT2A receptors: opposite effects of magnesium. Ann N Y Acad Sci 861:280
Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB (1990) Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1C receptors in rat brain. J Pharmacol Exp Ther 255(2):843–857
Barker EL, Westphal RS, Schmidt D, Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine 2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269(16):11687–11690
Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38(8):1083–1152
Baxter G, Kennett G, Blaney F, Blackburn T (1995) 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci 16(3):105–110
Berg KA, Maayani S, Goldfarb J, Clarke WP (1998) Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Ann N Y Acad Sci 861:104–110
Branchek T, Adham N, Macchi M, Kao HT, Hartig PR (1990) [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine 2 receptor. Mol Pharmacol 38(5):604–609
Brea J, Castro M, Giraldo J, Lopez-Gimenez JF, Padin JF, Quintian F, Cadavid MI, Vilaro MT, Mengod G, Berg KA, Clarke WP, Vilardaga JP, Milligan G, Loza MI (2009) Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol Pharmacol 75(6):1380–1391
Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387(6630):303–308
Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(23):3099–3108
Egan CT, Herrick-Davis K, Teitler M (1998) Creation of a constitutively activated state of the 5-hydroxytryptamine 2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286(1):85–90
Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K (2000) Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse 35(2):144–150
Glennon RA, Seggel MR, Soine WH, Herrick-Davis K, Lyon RA, Titeler M (1988) [125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors. J Med Chem 31(1):5–7
Hartman JI, Northup JK (1996) Functional reconstitution in situ of 5-hydroxytryptamine 2c (5HT2c) receptors with alphaq and inverse agonism of 5HT2c receptor antagonists. J Biol Chem 271(37):22591–22597
Hoyer D, Pazos A, Probst A, Palacios JM (1986) Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res 376(1):97–107
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46(2):157–203
Johnson MP, Hoffman AJ, Nichols DE, Mathis CA (1987) Binding to the serotonin 5-HT2 receptor by the enantiomers of 125I-DOI. Neuropharmacology 26(12):1803–1806
Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277(2):968–981
Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16(7):232–238
Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP (1997) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36(4–5):609–620
Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 370(2):114–123
Lefkowitz RJ, Cotecchia S, Samama P, Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14(8):303–307
Leonhardt S, Gorospe E, Hoffman BJ, Teitler M (1992) Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine 1C and 5-hydroxytryptamine 2 receptors. Mol Pharmacol 42(2):328–335
Lopez-Gimenez JF, Villazon M, Brea J, Loza MI, Palacios JM, Mengod G, Vilaro MT (2001) Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists. Mol Pharmacol 60(4):690–699
Lopez-Gimenez JF, Tecott LH, Palacios JM, Mengod G, Vilaro MT (2002) Serotonin 5-HT (2C) receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J Neurosci Res 67(1):69–85
Loric S, Launay JM, Colas JF, Maroteaux L (1992) New mouse 5-HT2-like receptor. Expression in brain, heart and intestine. FEBS Lett 312(2–3):203–207
McKenna DJ, Peroutka SJ (1989) Differentiation of 5-hydroxytryptamine 2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin. J Neurosci 9(10):3482–3490
McKenna DJ, Mathis CA, Shulgin AT, Sargent T III, Saavedra JM (1987) Autoradiographic localization of binding sites for 125I-DOI, a new psychotomimetic radioligand, in the rat brain. Eur J Pharmacol 137(2–3):289–290
McKenna DJ, Nazarali AJ, Hoffman AJ, Nichols DE, Mathis CA, Saavedra JM (1989) Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand. Brain Res 476(1):45–56
Nelson DL, Lucaites VL, Wainscott DB, Glennon RA (1999) Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol 359(1):1–6
Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346(2):205–230
Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 16(3):687–699
Pierce PA, Peroutka SJ (1989) Evidence for distinct 5-hydroxytryptamine 2 binding site subtypes in cortical membrane preparations. J Neurochem 52(2):656–658
Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23(1–2):163–178
Roth BL, Choudhary MS, Khan N, Uluer AZ (1997) High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine 2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther 280(2):576–583
Roth BL, Berry SA, Kroeze WK, Willins DL, Kristiansen K (1998) Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation. Crit Rev Neurobiol 12(4):319–338
Strange PG (1998) Three-state and two-state models. Trends Pharmacol Sci 19(3):85–86
Strange PG (1999) G-protein coupled receptors: conformations and states. Biochem Pharmacol 58(7):1081–1088
Teitler M, Leonhardt S, Weisberg EL, Hoffman BJ (1990) 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes. Mol Pharmacol 38(5):594–598
Waeber C, Palacios JM (1994) Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia. Brain Res Mol Brain Res 24(1–4):199–209
Westphal RS, Sanders-Bush E (1994) Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol Pharmacol 46(5):937–942
Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L (1995) Comparative localization of serotonin 1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol 351(3):357–373
Yadav PN, Kroeze WK, Farrell MS, Roth BL (2011) Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther 339(1):99–105
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
López-Giménez, J.F., Vilaró, M.T., Palacios, J.M. et al. Multiple conformations of 5-HT2A and 5-HT2C receptors in rat brain: an autoradiographic study with [125I](±)DOI. Exp Brain Res 230, 395–406 (2013). https://doi.org/10.1007/s00221-013-3636-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00221-013-3636-8